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Available online 3 July 2019Background: Children and young people (CYP) with chronic rheumatic conditions; Juvenile Idiopathic Arthritis,
Juvenile Systemic Lupus Erythematosus, Juvenile Dermatomyositis and Juvenile Vasculitis, treated with steroids,
have low bone density, increased fracture risk and are likely to have suboptimal peak bone mass. There is cur-
rently no evidence base for the management of steroid-induced bone loss in children with rheumatic diseases.
Methods:We undertook a multi-centre double dummy double-blind randomised placebo controlled trial to in-
vestigate whether the bisphosphonate risedronate was superior to alfacalcidol or calcium and vitamin D supple-
mentation in the prevention and treatment of steroid-induced osteopaenia in these children. Patients were
stratified and randomised in a 1:1 ratio, into: placebo; alfacalcidol; risedronate. The primary outcome was the
change in lumbar spine bonemineral density z score (LSaBMDz)measured by dual energy x-ray absorptiometry
at one year. Secondary outcome was fracture rate.
Results: Two hundred and seventeen patients were recruited to the study. Seventy seven placebo, 71 alfacalcidol,
and 69 risedronate. Highly statistically significant differences were observed in the change in LSaBMDz between
the placebo and risedronate groups; 0.274, 95%CI (0.061, 0.487) (p b 0.001) and between the risedronate and the
alfacalcidol groups; 0.326 95% CI (0.109, 0.543) (p b 0.001). The difference observed between the alfacalcidol and
placebo group was not statistically significant.
Highly statistically significant differences were seen in the change in Total Body Less Head aBMD-Z Score be-
tween the placebo and risedronate groups (p b 0.01) but not between the alfacalcidol and risedronate groups.
No significant differences in fracture frequency, adverse or serious adverse reactions were observed between
the groups.
Conclusions: Children and adolescents receiving steroids for rheumatic diseases benefit from prophylactic treat-
ment with bisphosphonates to increase LSaBMD. Alfacalcidol is ineffective.us Arthritis).
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Chronic rheumatic diseases of childhood affect between 1 and 3 per
1000 children in the UK [1,2]. Bone loss is a well-recognized major com-
plication with considerable morbidity [3]. Major contributory factors-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Many children and young people with rheumatic diseases are
treated with steroids for long periods. This, despite the advent of
biological therapies. Osteoporosis is one of the major complica-
tions of steroids. For adults there are currently numerous evi-
dence – based therapeutic strategies to prevent bone loss. No
such evidence exists for children and young people.
When the British Society for Paediatric Rheumatology
(BSPAR) surveyed paediatric rheumatologists in the UK regarding
their practice, in their children and youngpeople treatedwith ste-
roids, there was no consensus on which drugs to use for skeletal
protection (personal communication).
Calcium and vitamin D supplementation, or bisphosphonates
in those at higher risk, form the basis of current preventative
treatment strategies.
Older studies suggested calcitriol, or the calcitriol precursor
alfacalcidol, increased areal BMD in adults with steroid-induced
osteoporosis.
Two trials have studied the efficacy of bisphosphonates in chil-
drenwith rheumatic diseases; oneopen label study demonstrated
an improvement in aBMD whilst an underpowered RCT showed
no improvement. Two randomised trials, using bisphosphonates,
have been registered but both were abandoned due to failure to
recruit. This demonstrates the difficulty of undertaking such trials
in children and young people who are often quite ill due to their
disease and parents reluctance to engage in additional drug ther-
apies. A recent metanalysis found that the largest published pro-
spective treatment study included only 44 children. A 2007
Cochrane review concluded that there was insufficient evidence
to recommendbisphosphonates as standard therapy for the treat-
ment of secondary paediatric osteoporosis.
This is therefore the first and only fully powered randomised
controlled trial to investigate whether the bisphosphonate
risedronate or alfacalcidol results in clinical meaningful reduction
in bone loss in children and young people with rheumatic dis-
eases treated with steroids.
The primary aim of this study was to determine the efficacy of
risedronate or alfacalcidol compared to placebo in increasing lum-
bar spine aBMD z-score in children with rheumatic diseases, with
the secondary aim of assessing the effect of the interventions on
fracture rate.
The results of this trial will be of great value to paediatricians
and clinicians treating children and young people with steroids
providing the only evidence –base for the efficacy of a bisphos-
phonate in this situation.
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growth impairment [6], reduced physical activity [7] and treatment, par-
ticularly glucocorticoids [3,8,9]. Steroids are detrimental to bone stock,
however, despite the introduction of biologic drugs, for many children
steroids remain the only means by which their disease can be controlled.
Tens of thousands of children world-wide currently receive steroids for
chronic rheumatic conditions. Steroids reduce peak bone mass and frac-
ture risk increases as steroid dose increases [3,9,10]. Manymore children
receive recurrent courses of steroids for other common diseases such as
asthma, with an associated increased risk of fracturing [11,12].
Children receiving steroids can, unlike adults, dramatically increase
their BMD when their disease is brought under control [13]. There is
thus a tension between effective disease control and the adverse effects
of the steroid therapy.
The current guidelines for adults are that those treated with GCs
should receive prophylactic treatment for the prevention of bone loss
[14]. No such recommendations are in place for children.When the British Society for Paediatric Rheumatology (BSPAR) sur-
veyed paediatric rheumatologists in the UK regarding their practice,
there was no consensus on which drugs to use for skeletal protection
(personal communication).
Calcium and vitamin D supplementation, or bisphosphonates in
those at higher risk, form the basis of current preventative treatment
strategies.
Older studies suggested calcitriol, or the calcitriol precursor
alfacalcidol, increased aBMD in adults with steroid-induced osteoporo-
sis [15,16].
Two trials have studied the efficacy of bisphosphonates in children
with rheumatic diseases; one open label study demonstrated an im-
provement in aBMDwhilst an underpowered RCT showed no improve-
ment [17,18]. A 2007 Cochrane review concluded that there was
insufficient evidence to recommend bisphosphonates as standard ther-
apy for the treatment of secondary paediatric osteoporosis [19]. A recent
metanalysis found that the largest published prospective treatment
study included only 44 children [20].
The primary aim of this study was to determine the efficacy of
risedronate or alfacalcidol compared to placebo in increasing lumbar
spine aBMD z-score in children with rheumatic diseases, with the sec-
ondary aim of assessing the effect of the interventions on fracture rate.
2. Methods
This randomised double blind placebo controlled trial was con-
ducted on behalf of the British Society of Paediatric and Adolescent
Rheumatology (BSPAR); the study was approved by OREC Northern
Ireland and registered with EuDRACT No: 2005-003129-23;
ISRCTN66814619.
Patients were recruited from eleven sites throughout the UK. Trial
duration was one year with three months post-trial follow-up. The
trial ran from 22/Aug/2007 to 27/Feb/2013.
Children and adolescents with Juvenile Idiopathic Arthritis (JIA), Ju-
venile Systemic Lupus Erythematosus (JSLE), Juvenile Dermatomyositis
(JDM) or vasculitis, between the ages of four and 18 years, commencing
or established on steroid therapy, were eligible to participate. Protocol
details are in Supplementary data.
Written informed consent was obtained from all parents/guardians
and consent/assent obtained from all patients prior to starting the
study.
Participants were stratified according to:
⁎ Tanner stage (0–2; 3–5)
⁎ Steroid dose (prednisolone equivalent) (Low ≤0.2 mg/kg/d) Vs
medium-high (N0.2 mg/kg/d)
Subjects were randomised in an independent central randomisation
facility (Clinical Research Support Centre NI) into three groups, accord-
ing to stratification information included in the registration form, in
a1:1 ratio to receive:
Group 1. Alfacalcidol/risedronate placebo.
Group 2. Alfacalcidol 15 ng/kg/day (max 1 μg).
Group 3. Risedronate 1 mg/kg/week for body weight b 30kgs, or
35 mg/wk. for body weight N 30 kgs.
The risedronate and risedronate placebo were identical as were the
alfacalcidol and placebo.
All children received a supplement of 500mg calcium and 400 IU vi-
tamin D daily.
The research nurse faxed the registration information to the CRSC
where they were randomised to receive a study number which the re-
search nurse obtained by Fax. Simultaneously the trial pharmacist in
each study centre received the same number to dispense the appropri-
ated coded and blinded medication. The study pharmacists were not
blinded to the treatment dispensed. They had no further involvement
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ents were blinded to the study treatment.
2.1. Visit schedule
Patients were assessed and randomised to treatment group at T0,
and assessed every three months until study end. Throughout the
trial, changes in anti-rheumatic therapy, including steroid dosage,
were permitted according to locally-defined clinical need.
2.2. Clinical assessment
The clinical parameters assessed at each visit were; height, weight
skin fold thickness, Tanner score, JIA disease activity, (Childhood Health
Assessment Questionnaire, British Isles Lupus Assessment Group Index,Fig. 1. CONSORT flChildhoodMyositis Assessment Score, fracture history. Allmenstruating
females were tested for pregnancy.
2.3. Laboratory measurements
The following parameters were assessed in blood and urine at each
visit. Samples were not obtained fasting as this was logistically difficult
in children and would not be feasible in normal clinical practice.
Full blood picture (FBP); Erythrocyte sedimentation rate (ESR); C-
reactive protein (CRP); Urea and Electrolytes (U&E); Bone profile;
Urine Calcium/Creatinine ratio every 3 months. All centres used their
hospital's standard ranges which were stored in the site files. Serum
25 hydroxyvitamin D (Immunodiagnostics, UK) and parathormone
(Abbot Diagnostics, UK), bone alkaline phosphatase, Osteocalcin (mea-
sures of bone formation), and Crosslaps (measure of bone resorption)
(Roche diagnostics, UK) were measured at T = 0 and at 3 months. Theow diagram.
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reference range was used for Crosslaps [21].
2.4. Radiological assessment
In the 11 participating centres, seven DXA scanners were Lunar
Prodigy and four were Hologic. All participating DXA scanners were
standardised using a paediatric spine phantom (MRC Mineral Metabo-
lism Unit, Leeds, UK) [22]. The initial DXA scans were performed within
two weeks of commencing the study and lumbar spine areal BMD
(LSaBMD) and total body less head areal BMD (TBLHaBMD) were mea-
sured then and at visit 3 (6months) and at visit 5 (12months). LSaBMD
and TBLHaBMD z-scores were either machine-derived or, for five pa-
tients under age five years, calculated by the Least Median Squares
(LMS) method using UK reference data [23,24].
Lateral radiographs of the spine for vertebral deformity were per-
formed at baseline and month 12. All radiographs were read centrally
and blindly by a consultant musculoskeletal radiologist (ME). Vertebral
fractures were scored 0–3 using the Genant method [25] where grade
0: normal; grade 1: mild fracture, 20% to 25% loss of height; grade 2:
moderate fracture, 25% to 40% loss of height; grade 3: severe fracture,
greater than 40% loss of height.
2.5. Safety
Urinary calcium excretion was recorded as a safety measure. The
numbers of patients experiencing adverse events (AEs) or serious adverse
events (SAEs) and number of events are reported by treatment group. An
adverse event is any untoward medical occurrence in a patient in the
study. An adverse reaction (AR) is defined as any AE considered to have
a possible, probable or definite relationship to the study drug.
2.6. Study details
Risedronate and its placebo were provided by Proctor and Gamble
(subsequently Warner Chilcott UK). Alfacalcidol was obtained fromTable 1
Baseline characteristics (population: intention to treat (ITT).
Variables
N
Age (years), mean (SD)
Gender Female, n (%)
Male, n (%)
Tanner score, median (IQR)
Steroid dose, n
(%)
≤0.2 mg/kg
N0.2 mg/kg
Ethnic origin, n
(%)
Caucasian
Black
Oriental
Asian
Other
Disease group, n
(%)
JIA
JSLE
JDM
Vasculitis
Approximate cumulative steroid dose mg, mean (SD) (n = 206)a
Relevant medical conditionsb (yes), n (%)
On any medications at baseline
DMARDSc
Methotrexate, Mycophenolate Mofetil, Azathioprine, Cyclophosphamid
Hdroxychloroquine, Cyclosporine
Biologics: Etanercept; Infliximab; Anakinra; Tocilizumab
Prior fracture history (yes), n (%)
a One patient in placebo had a cumulative steroid dose of 238,325 mg and one patient in the
mean (SD) calculation.
b Details of relevant medical conditions are available in Table 1.
c Disease modifying anti rheumatic drugs.Leo Laboratories (One Alpha, Leo laboratories) and the alfacalcidol pla-
cebo was made by Victoria Pharmaceuticals, Belfast Hospital Trust. Cal-
cium and vitamin D supplements were supplied by Victoria
Pharmaceuticals.
None of the pharmaceutical companies had any input into the trial
design or data analysis.
2.7. Study oversight
The study was designed by the authors and the trial data input and
analysis undertaken by the Northern Ireland Clinical Trials Unit
(NICTU). The progress of the trial was monitored by the Data Monitor-
ing and Ethics Committee of Arthritis Research UK (now Versus Arthri-
tis). Data analysis was conducted by three of the authors.
2.8. Sample size calculation
There was little existing evidence on what was regarded as a clini-
cally meaningful effect size.
The initial required sample size was 270 children. To detect an im-
provement between the treatment groups of 6.25 and between the
treatment groups and the control groups of 6.25, using a SD of 12.5, ob-
served in our 1 year growth hormone study [6], 75 children were re-
quired in each of the three study arms; with 80% power to detect a
significant difference at the 5% level of significance.We further expected
a dropout rate of 15%, and that approximately 20% of this population
would not receive steroids for one year. Thus to ensure that an adequate
number of children would complete the study on steroids we required
90 children per treatment group; a total of 270.
Interim analysis showed that there was much better retention rate
and fewer stopping steroids. There were two re-assessments of sample
size calculation. One assessment after reducing percentage of patients
without efficacy endpoint as 15% and another re-calculation was done
with 10% dropouts. The effect size was kept the same. The sample size
was set to 216, with 10% drop out rate.Placebo Alfacalcidol Risedronate All Patients
77 71 69 217
12.1 (3.5) 12.1 (3.7) 12.0 (3.4) 12.1 (3.5)
55 (71.4) 48 (67.6) 53 (76.8) 156 (71.9)
22 (28.6) 23 (32.4) 16 (23.2) 61 (28.1)
2 (1 to 4) 2 (1 to 4) 2 (1 to 3) 2 (1 to 4)
37 (48.0) 30 (42.2) 32 (46.4) 99 (45.6)
40 (52.0) 41 (57.8) 37 (53.6) 118 (54.4)
59 (76.6) 54 (76.1) 55 (79.7) 168 (77.4)
4 (5.2) 4 (5.6) 6 (8.7) 14 (6.4)
0 (0) 1 (1.4) 0 (0) 1 (0.5)
11 (14.3) 10 (14.1) 6 (8.7) 27 (12.4)
3 (3.9) 2 (2.8) 2 (2.9) 7 (3.2)
21 (27.3) 30 (42.2) 20 (29.0) 71 (32.7)
31 (40.3) 21 (29.6) 24 (34.8) 76 (35.0)
17 (22.1) 13 (18.3) 16 (23.2) 46 (21.2)
11 (14.3) 12 (16.9) 13 (18.8) 36 (16.6)
8403.7
(9206.9)
9108.7
(7528.0)
8090.4
(9390.1)
8531.5
(8721.8)
42 (55.3) 39 (54.9) 43 (62.3) 124 (57.4)
75 (98.7) 69 (97.2) 68 (98.6) 212 (98.2)
e,
71 (93.4) 64 (90.1) 62 (89.9) 197 (91.2)
8 (10.5) 17 (23.9) 7 (10.1) 32 (14.8)
13 (17.1) 9 (12.7) 8 (11.6) 30 (13.89)
alfacalcidol arm had a cumulative dose of 487,400mg. These values were excluded in the
Table 2
Steroid doses anthropometric values and disease activitymarkers at baseline and one year
(population: ITT).
Variable Visit Mean (SD)
Placebo Alfacalcidol Risedronate
Daily Prednisolonea
Mean ± SD
Baseline 76
12.20 (8.83)
70
13.83 (10.97)
69
16.91 (22.69)
One year
65
5.88 (6.40)
59
5.82 (4.83)
55
6.17 (5.44)
Height cms Baseline 145.0 (18.6) 145.3 (21.3) 144.6 (19.9)
One year 149.0 (15.5) 149.9 (20.2) 148.7 (19.2)
Weight Kg Baseline 46.14 (17.41) 48.24 (20.79) 48.05 (18.87
One year 49.82 (17.85) 53.62 (23.08) 51.56 (18.79)
Hb g/dl Baseline 12.8 (1.36) 12.6 (1.31) 12.5 (1.25)
One year 12.6 (1.53) 12.5 (1.14) 12.5 (1.12)
ESR mm/h Baseline 14.7 (17.1) 16.2 (13.6) 14.7 (16.7)
Fig. 2. Kaplan-Meier survival curves. Time to study drug withdrawal according to treatment group (population: ITT).
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The efficacy measure was the change in BMD at year 1 follow-up
from baseline. The primary outcome measure was the change from
baseline in LSaBMD z-score and the primary analysis was carried out
using ANOVA, to test whether there is a statistically significant differ-
ence between the groups. The post-hoc bonferroni test was carried
out to checkwhich pair differ significantly. (Placebo vs. Alfacalcidol, Pla-
cebo vs. Risedronate, Alfacalcidol vs. Risedronate).
Analysis of covariance was performed on Lumbar spine BMD at year
1 adjusting for Lumbar spine BMD at baseline, age and gender. A post-
hoc pairwise comparison was carried out using Bonferroni test.
Patients whose drug was prematurely withdrawn were encouraged
to have a DXA scan at one year and their results included in the analysis.
Intention-to- treat (ITT) population includes all patients who were
randomised and who received at least one dose of the planned study
medication. Per protocol analysis includes all the patients who received
all doses of the study drug as per protocol.
The primary efficacy analysis was based on the ITT population, but a
per-protocol analysiswas also performed. Final analysiswas unadjusted
for the interim analysis.
The Secondary Outcome was the rate of vertebral or other fractures
during the trial period.
Count of observations, mean ± SD, median (p25 to p50), and fre-
quency (percentage) were used to summarise the variables.One year 11.0 (11.7) 15.9 (17.8) 16.0 (21.5)
CRP mg/L Baseline 5.2 (5.8) 7.8 (11.4) 7.8 (9.5)
One year 4.8 (5.2) 6.2 (6.2) the5.7 (5.7)
ALP IU/L Baseline 187.0 (126.6) 196.1 (133.2) 179.1 (112.4)
One year 217.8 (158.5) 233.4 (191.9) 214.9 (155.8)
One in placebo, 4 in alfacalcidol and 4 in risedronate groups. For these, the daily prednis-
olone equivalent was calculated.
a Two patients were treated with deflazacort, and one hydrocortisone. Nine patients
received methylprednisolone pulses.3. Results
Two hundred and seventeen patients were recruited from 11 partic-
ipating centres throughout theUK and randomised to placebo (n=77),
alfacalcidol (n = 71), or risedronate (n = 69). Screening and recruit-
ment information are shown in the consort flow diagram Fig. 1.Baseline demographics are shown in Table 1.
Ethnicity, gender, age, disease subtype, Tanner stage and ste-
roid dose were evenly distributed between the three groups.
There was no significant difference in the fracture history between
the groups.
Some 90% of participants in each groupwere concurrently treated
with a DMARD and biologic use was 10.5%, 23.9% and 10.1% in the
three groups respectively. Five patients in the placebo group started
steroids de novo and two in the alfacalcidol group. All other patients
Table 3
Areal BMD gm/cm2 and areal BMD z-scores over during the course of the study (popula-
tion: ITT).
N, mean (SD)
Placebo Alfacalcidol Risedronate
Lumbar Spine aBMD g/cm2
Screening 76, 0.76 (0.20) 71, 0.79 (0.21) 68, 0.78 (0.19)
6 month 68, 0.79 (0.18) 63, 0.80 (0.22) 59, 0.82 (0.19)
One-year 72, 0.80 (0.19) 67, 0.83 (0.21) 58, 0.85 (0.17)
Lumbar spine aBMD z score
Screening 76,−1.15 (1.15) 68,−0.91 (1.04) 66,−1.04 (1.17)
Screening-calculateda 76,−1.15 (1.15) 71,−0.96 (1.04) 68,−0.99 (1.19)
6 month 68,−1.17 (1.07) 61,−0.95 (1.12) 57,−0.84 (1.16)
6 month-calculateda 68,−1.17 (1.07) 63,−1.01 (1.15) 59,−0.79 (1.18)
One-year 72,−1.13 (1.10) 67,−0.99 (1.07) 58,−0.74 (1.17)
One-year-calculateda 72,−1.13 (1.10) 67,−1.00 (1.07) 58,−0.75 (1.15)
Total body less head aBMD g/cm2
Screening 75, 0.91 (0.14) 70, 0.93 (0.16) 68, 0.91 (0.13)
6 month 68, 0.93 (0.13) 62, 0.94 (0.17) 58, 0.93 (0.13)
One-year 70, 0.92 (0.12) 65, 0.97 (0.16) 59, 0.96 (0.13)
Total body less head aBMD z score
Screening 75,−0.57 (0.99) 67,−0.4 (1.09) 66,−0.63 (1.08)
Screening-calculateda 75,−0.57 (0.99) 70,−0.63 (1.64) 68,−0.65 (1.08)
6 month 68,−0.62 (0.99) 59,−0.29 (1.19) 56,−0.50 (1.08)
6 month-calculateda 68,−0.62 (0.99) 62,−0.49 (1.55) 58,−0.52 (1.08)
One-year 70,−0.70 (0.94) 65,−0.46 (1.28) 59,−0.46 (1.09)
One-year-calculateda 70,−0.70 (0.94) 65,−0.57 (1.47) 59,−0.44 (1.08)
Least Median Squares (LMS) method [22].
a Includes z-scores for five patients (all visits) who were below five years of age that
were calculated using.
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cumulative steroid dose from the available patient records, prior to
the commencement of the trial averaged 8–9 g in each group. Details
of relevant medical conditions are available in Table 1 of Supplemen-
tary data.
Kaplan Meier survival curves demonstrate similar retention rates
between the three groups Fig. 2, although a slightly earlier drop outTable 4
Efficacy analysis: change in areal BMD and areal BMD z-scores from baseline to one year (pop
Change from baseline to
1 year
Mean (SD) p-Value Alfacalc
Placebo Alfacalcidol Risedronate Mean d
(95% CI)
Primary outcome measure: change in lumbar spine aBMD-Z score
Primary analysis - ITT −0.036
(0.435)
−0.088
(0.519)
0.238
(0.551)
0.0007 −0.052
0.153)
Per protocol −0.043
(0.431)
−0.036
(0.510)
0.264
(0.540)
0.0008 0.007 (−
0.219)
ANCOVA 0.0004 −0.024
0.171)
Change in lumbar spine aBMD g/cm2
ITT 0.034
(0.047)
0.031
(0.052)
0.069
(0.057)
0.0001 −0.002
0.019)
Per protocol 0.034
(0.048)
0.036
(0.051)
0.072
(0.055)
0.0001 0.002 (−
0.024)
ANCOVA 0.0001 −0.001
0.021)
Change in total body less head aBMD g/cm2
ITT 0.016
(0.032)
0.029
(0.034)
0.040
(0.030)
0.0001 0.014 (0
Per protocol 0.016
(0.032)
0.032
(0.034)
0.041
(0.030)
0.0001 0.015 (0
Change in total body less head aBMD-Z score
ITT −0.129
(0.458)
0.012
(0.505)
0.169
(0.415)
0.0016 0.141 (−
0.333)
Per protocol −0.103
(0.448)
0.067
(0.476)
0.182
(0.415)
0.0021 0.170 (−
0.365)was noted in the risedronate group, there was no statistical difference
between them.
Eighty four percent, 86% and 81% of the placebo, alfacalcidol and
risedronate groups respectively were still taking steroids at one
year with mean daily intake of 5.88; 5.82 and 6.17 mg of predniso-
lone daily respectively. Clinical indicators of disease activity were
similar at one year as were biochemical markers of disease activity
Table 2.3.1. Efficacy analysis
The primary outcomewas the change in LSaBMD z-score at one year
from baseline which together with LSaBMD, TBLHaBMD, and
TBLHaBMD z-score are summarised in Table 3, with the efficacy analysis
in Table 4. For transparency the BMDvalueswithout andwith the calcu-
lated results are shown. For all subsequent aBMD results in subsequent
tables, the values shown are the calculated values.
During the year of treatment, LSaBMD z-score was unchanged in the
placebo group;−1.15 to−1.13; decreased from−0.96 to−1.00 in the
alfacalcidol group and increased from −0.99 to −0.75 in the
risedronate group.
LSaBMD and TBLHaBMD increased in all groups, the largest increase
being in the risedronate group, the least in the placebo group.
Forest plots for mean (95% CI) change in lumbar spine BMD
Score according to treatment group and tanner score and treatment
group and steroid dose can be seen in Figs. 1 and 2 in Supplemen-
tary data.
The primary analysis using ANOVA showed that there was a sta-
tistically significant difference between the groups (p = 0.0007).
Highly significant differences were observed between the change
in LSaBMD z-scores between the placebo and risedronate groups;
0.274, (95% CI 0.061, 0.487; p b 0.001) and between the risedronate
and the alfacalcidol groups; 0.326 (95% CI 0.109, 0.543; p b 0.001)
but not between the placebo and alfacalcidol groups; −0.052
(−0.257, 0.153). The ANCOVA on LSaBMD z-score at one year, after
adjusting for baseline covariates, showed that there is statisticallyulation: ITT).
idol vs placebo Risedronate vs placebo Risedronate vs alfacalcidol
ifference p-Value Mean difference
(95% CI)
p-Value Mean difference
(95% CI)
p-Value
(−0.257, 1.0 0.274 (0.061,
0.487)
0.007 0.326 (0.109,
0.543)
0.001
0.204, 1.0 0.307 (0.092,
0.521)
0.002 0.300 (0.078,
0.522)
0.004
(−0.219 to 1.0 0.286 (0.083 to
0.488)
0.002 0.311 (0.104 to
0.516)
0.001
(−0.023, 1.0 0.036 (0.014,
0.058)
b0.001 0.038 (0.015,
0.060)
b0.001
0.020, 1.0 0.038 (0.015,
0.060)
b0.001 0.036 (0.013,
0.059)
0.001
(−0.022, 1.0 0.036 (0.014,
0.059)
b0.001 0.037 (0.015,
0.060)
b0.001
.001, 0.027) 0.035 0.025 (0.011,
0.038)
b0.001 0.011 (−0.003,
0.025)
0.1
.002, 0.029) 0.024 0.025 (0.011,
0.039)
b0.001 0.010 (−0.005,
0.024)
0.3
0.051, 0.2 0.298 (0.101,
0.495)
0.001 0.157 (−0.043,
0.358)
0.1
0.024, 0.1 0.285 (0.090,
0.481)
0.002 0.115 (−0.086,
0.317)
0.5
85M. Rooney et al. / EClinicalMedicine 12 (2019) 79–87significant between group difference (p= 0.0004) Table 4 shows the
mean (95% CI) for the pairwise comparisons post ANCOVA. Fig. 3.
3.2. Fracture data
Non-vertebral fracture rates in the placebo, alfacalcidol and
risedronate groups were 5.3 (n = 4), 2.8 (n = 2) and 7.2 (n = 5) re-
spectively. There was no statistically significant difference in the frac-
ture rate between the treatment groups (Fisher's exact p = 0.51).
One hundred and eighty-seven patientswith pre and post treatment
lateral spinal X-rays were scored, using the Genant scoring system. Fifty
four patients in the Placebo arm had baseline Genant score of 0 which
remained unchanged for all at one year. In the alfacalcidol group, in all
of the 52 patients with baseline and one year radiographs the Genant
score remained unchanged (50 scored 0, 1 scored 2, 1 scored 3). In thePlacebo Alfacalcid
Fig. 3. a) Lumbar spine BMD, b) lumbar spine BMD Z-score, c) total body less head areal BMD a
study (population: ITT).risedronate group, all the 53 patients had a Genant score of 0 at base-
line; at one year 50 remained unchanged, 2 had a Genant score of 1
and 1 had a Genant score of 3.
3.3. Biochemical and haematological parameters
There were no statistically significant differences in the biochemical
profiles between the three treatment groups at baseline and at
3 months and one year. Twenty-five hydroxy Vitamin D levels were
similar in all three groups at baseline and increased in all three groups
at 3 months. Alkaline phosphatase increased in all three groups over
one year. PTH (ng/l) fell in both the placebo and alfacalcidol groups dur-
ing the first 3 months from 39.8 (19.9) to 32.6 (20.1) and 34.8 (19.9) to
28.2(17.6) respectively, whilst in the risedronate group it rose from 41
(24.2) to 45.4 (31.9). No change was observed in either calcium orol Risedronate
nd d) total body less head areal BMD z-scores by treatment group during the course of the
Table 6
Adverse events and serious adverse event summary (safety population).
Placebo n = 77 Alfacalcidol n =
71
Risedronate n =
69
Number of patients
Experiencing an AE
n 62 59 59
Proportion (95%
CI)
0.81 (0.70 to
0.89)
0.83 (0.72 to
0.91)
0.86 (0.75 to
0.93)
Experiencing an SAE
n 18 14 21
Proportion (95%
CI)
0.23 (0.14 to
0.34)
0.20 (0.11 to
0.31)
0.30 (0.20 to
0.43)
Number of events
Number of AEs 308 260 292
Proportion (95% CI) 0.36 (0.33 to
0.39)
0.30 (0.27 to
0.33)
0.34 (0.31 to
0.37)
Number of ARsa 17 11 15
Proportion (95% CI) 0.40 (0.25 to
0.56)
0.26 (0.14 to
0.41)
0.35 (0.21 to
0.51)
Number of SAEs 21 22 31
Proportion (95% CI) 0.28 (0.19 to
0.40)
0.30 (0.20 to
0.41)
0.42 (0.31 to
0.54)
Number SARs 0 2 1
Proportion (95% CI) 0.33 (0.01 to
0.91)
0.67 (0.09 to
0.99)
0 (0.0 to 0.71)
a AnAEwith a definite/probable/possible relationship to the study drug is considered as
an AR.
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between the three groups throughout the year of the study (see
Table 5).
3.4. Bone markers
Changes in bone alkaline phosphatase, osteocalcin and crosslaps are
shown in Supplementary data Table 2. None of the bone markers pre-
dicted the change in BMD at one year.
3.5. Safety
Among 217 patients whowere randomised to the trial, 215 patients
received at least one dose of study drug and 180 patients experienced at
least one adverse event. There was no statistically significant difference
between the number of patients experiencing AEs and SAEs between
the groups. Higher SAEs were observed in the risedronate group com-
pared to placebo group but only one of these was an adverse reaction
i.e. possibly related to the treatment (Table 6). Further details on the
types of SAEs are available in Supplementary data Table 3.
4. Discussion
We have demonstrated that the bisphosphonate risedronate signifi-
cantly increased LSaBMD z-score in children and young people (CYP)
receiving steroids for the treatment of their rheumatological disease,
compared to those receiving alfacalcidol or vitamin D and calcium
alone. The improvement in LSaBMD z-score for our CYP treated with
risedronate was substantially greater than the increases in BMD typi-
cally observed in adult studies of glucocorticoid-induced osteoporosis
[26]. Our trial was not powered to study the impact of risedronate on
fracture rates in CYP; such a trial might require several thousand partic-
ipants. We observed a 28% increase in BMD z-score in children treated
with risedronate compared to a 2% increase and a 10% decrease in CYP
treated with placebo or alfacalcidol. Whilst one cannot draw a direct
comparison between improvements in adult and CYP BMD T and Z
scores, very modest improvements of 6% in BMD in women treated
with a bisphosphonate resulted in an almost halving of fractures [27]
Furthermore in a study of childrenwith osteogenesis imperfecta treated
with bisphosphonates a difference in z-score of 0.387 between the
treated and placebo groups was associated with a 47% decrease in frac-
ture rate [28].
This is the first fully powered blinded randomised controlled trial
into the prevention and treatment of osteopenia in this population.
Two previous RCTs were terminated due to failure to recruit demon-
strating the difficulty of undertaking such trials in CYP [29,30].
We suggest that in association with our observed increase in BMD,
fracture risk should also be reduced, even though the observed increase
in LSaBMD z-score was less than the hoped-for 0.5.Table 5
Mean (SD) of biochemical parameters by treatment arm (population: ITT).
Variable Visit Placebo Alfacalcidol Risedronate
Calcium mmol/l Baseline 2.4 (0.1) 2.4 (0.1) 2.4 (0.1)
One year 2.4 (0.1) 2.4 (0.1) 2.4 (0.1)
Phosphate mmol/l Baseline 1.4 (0.2) 1.3 (0.3) 1.3 (0.2)
One year 1.4 (0.2) 1.3 (0.3) 1.3 (0.2)
25 hydroxy
Vitamin D nmol/l
Baseline 49.2 (28.5) 50.2 (26.6) 44.8 (26.7)
3 montha 59.9 (24.8) 67.1 (41.3) 63.5 (32.8)
PTH ng/l Baseline 39.8 (19.9) 34.8 (19.9) 41.0 (24.2)
3 month 32.6 (20.1) 28.7 (17.6) 45.4 (31.9)
ALP IU Baseline 187.0 (126.6) 196.1 (133.2) 179.1 (112.4)
One year 217.8 (158.5) 233.4 (191.9) 214.9 (155.8)
CRP mg/l Baseline 5.2 (5.8) 7.8 (11.4) 7.8 (9.5)
One year 4.8 (5.2) 6.2 (6.2) 5.7 (5.7)
a Some parameters were only measured at baseline and 3 months.Many paediatric rheumatologists use alfacalcidol rather than
bisphosphonates, as they consider it safer; there was evidence that
this prodrug could also improve BMD in adult patients treated with ste-
roids [15,16]. Our study demonstrates that alfacalcidol has no impact on
LSaBMD z-score in children with inflammatory conditions receiving
glucocorticoids. Alfacalcidol did result in a significant improvement in
TBLHaBMD, but not TBLHaBMD z-score, that is, not after accounting
for changes due to age and sex. Alfacalcidol is not without risk; as it by-
passes the normal renal regulation, excessive alfacalcidol administra-
tion can result in serious hypercalcaemia and organ damage [31].
The acquisition of adequate peakbonemass is not only important for
the young person in reducing fracture risk but also has significant impli-
cations for the development of osteoporosis in later life, if peak bone
mass is suboptimal.
We had hoped that early changes in bone markers might identify
those patients whowere or were not responding to treatment, allowing
timely changes to be made to patient's management. However in our
population, bone markers were not able to predict which patients
responded best to treatment. Alkaline phosphatase levels increased in
all three treatment groups over time as would be expected in growing
CYP. The increase in PTH levels in the risedronate group at 3 months is
probably due to the effective inhibition of bone resorption which in-
duces a reduction in serum calcium leading to increased parathyroid
hormone (PTH) levels.
All therapeutic interventions were well tolerated and the side ef-
fect profiles were similar between all three groups. Whilst SAEs in
the risedronate group were 7% higher than in the control group
there was no difference in the SARs where the reactions were consid-
ered to be related to the treatment. SAEs in the risedronate group
and were primarily related to disease flares. This study is not large
enough to evaluate whether bisphosphonates might induce disease
flares. I should be noted that the participants in this trial all hadmod-
erate to severe disease, requiring steroids, thus disease flares would
be expected.
Avascular necrosis of the mandible has been reported in adults
treated with bisphosphonates [32]. We had no such cases and have
not identified any in the literature in children.
The long-term effects of bisphosphonates in growing children have
as yet not been fully evaluated, although longitudinal cohort studies of
87M. Rooney et al. / EClinicalMedicine 12 (2019) 79–87children with OI (most often exposed to these drugs) are generally
reassuring [33].
5. Conclusion
We have demonstrated that the bisphosphonate risedronate results
in statistically and, we believe, clinically meaningful increases in bone
mass in both the whole body and the lumbar spine, a site at particular
risk for fracture in children with low bone mass in association with in-
flammatory conditions. The drug was well tolerated with no significant
increase in side effects over the comparators. We would advise consid-
eration of risedronate in children and young people with inflammatory
conditions receiving steroids, especially those considered at higher risk
for fracture.
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